File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Serum concentration of soluble interleukin 2 receptors in asthma: Correlation with disease activity

TitleSerum concentration of soluble interleukin 2 receptors in asthma: Correlation with disease activity
Authors
Issue Date1993
PublisherAmerican College of Chest Physicians. The Journal's web site is located at http://www.chestjournal.org
Citation
Chest, 1993, v. 103 n. 3, p. 782-786 How to Cite?
AbstractWe evaluated whether serum soluble interleukin 2 receptor (sIL-2R), a marker of T lymphocyte activation in vivo, could be useful to monitor disease activity in asthma. Venous blood was collected from 26 patients with acute severe asthma prior to the commencement of systemic corticosteroid therapy (day 1), 15 with stable disease, and 13 normal control subjects. Serum sIL- 2R level was significantly higher in acute asthma (462.7±36.1 U/ml; mean±SEM) than stable disease (328.5±30.4 U/ml, p=0.013) which in turn, was significantly raised when compared with control subjects (239.0±22.9 U/ml; p=0.0003 vs acute; p=0.036 vs stable). Nevertheless, sIL-2R concentrations in 11 patients with acute and 11 with stable disease did not exceed the upper limit of normal, ie, mean +2 SD of the value in control subjects = 404.4 U/ml. Repeated measurements of sIL-2R in 24 acute asthmatics on day 3 revealed no significant fall (464.6±37.2 U/ml, NS), although the reduction in sIL-2R was significantly correlated with the corresponding improvement in peak expiratory flow (r = -0.52, p=0.005). Following resolution of the acute attack, further measurements performed in 11 of these subjects on day 28 showed a significant fall in sIL-2R (p=0.016). Our data showed that although serum sIL-2R was raised in asthma and, to a certain extent, might reflect disease activity, the considerable overlap of values between asthma of differing severity and normal control subjects precludes its clinical use as an index of asthma severity.
Persistent Identifierhttp://hdl.handle.net/10722/162005
ISSN
2015 Impact Factor: 5.94
2015 SCImago Journal Rankings: 3.176
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLai, CKWen_HK
dc.contributor.authorChan, CHSen_HK
dc.contributor.authorLeung, JCKen_HK
dc.contributor.authorLai, KNen_HK
dc.date.accessioned2012-09-05T05:16:35Z-
dc.date.available2012-09-05T05:16:35Z-
dc.date.issued1993en_HK
dc.identifier.citationChest, 1993, v. 103 n. 3, p. 782-786en_HK
dc.identifier.issn0012-3692en_HK
dc.identifier.urihttp://hdl.handle.net/10722/162005-
dc.description.abstractWe evaluated whether serum soluble interleukin 2 receptor (sIL-2R), a marker of T lymphocyte activation in vivo, could be useful to monitor disease activity in asthma. Venous blood was collected from 26 patients with acute severe asthma prior to the commencement of systemic corticosteroid therapy (day 1), 15 with stable disease, and 13 normal control subjects. Serum sIL- 2R level was significantly higher in acute asthma (462.7±36.1 U/ml; mean±SEM) than stable disease (328.5±30.4 U/ml, p=0.013) which in turn, was significantly raised when compared with control subjects (239.0±22.9 U/ml; p=0.0003 vs acute; p=0.036 vs stable). Nevertheless, sIL-2R concentrations in 11 patients with acute and 11 with stable disease did not exceed the upper limit of normal, ie, mean +2 SD of the value in control subjects = 404.4 U/ml. Repeated measurements of sIL-2R in 24 acute asthmatics on day 3 revealed no significant fall (464.6±37.2 U/ml, NS), although the reduction in sIL-2R was significantly correlated with the corresponding improvement in peak expiratory flow (r = -0.52, p=0.005). Following resolution of the acute attack, further measurements performed in 11 of these subjects on day 28 showed a significant fall in sIL-2R (p=0.016). Our data showed that although serum sIL-2R was raised in asthma and, to a certain extent, might reflect disease activity, the considerable overlap of values between asthma of differing severity and normal control subjects precludes its clinical use as an index of asthma severity.en_HK
dc.languageengen_US
dc.publisherAmerican College of Chest Physicians. The Journal's web site is located at http://www.chestjournal.orgen_HK
dc.relation.ispartofChesten_HK
dc.subject.meshAcute Diseaseen_US
dc.subject.meshAdrenal Cortex Hormones - Administration & Dosageen_US
dc.subject.meshAdrenergic Beta-Agonists - Administration & Dosageen_US
dc.subject.meshAdulten_US
dc.subject.meshAsthma - Blood - Drug Therapyen_US
dc.subject.meshBiological Markers - Blooden_US
dc.subject.meshBronchial Provocation Testsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHistamine - Diagnostic Useen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshReceptors, Interleukin-2 - Analysis - Drug Effectsen_US
dc.subject.meshSolubilityen_US
dc.subject.meshTime Factorsen_US
dc.titleSerum concentration of soluble interleukin 2 receptors in asthma: Correlation with disease activityen_HK
dc.typeArticleen_HK
dc.identifier.emailLeung, JCK: jckleung@hku.hken_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.authorityLeung, JCK=rp00448en_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1378/chest.103.3.782-
dc.identifier.pmid8095448-
dc.identifier.scopuseid_2-s2.0-0027479175en_HK
dc.identifier.volume103en_HK
dc.identifier.issue3en_HK
dc.identifier.spage782en_HK
dc.identifier.epage786en_HK
dc.identifier.isiWOS:A1993KQ38200026-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLai, CKW=7403086390en_HK
dc.identifier.scopusauthoridChan, CHS=16169208100en_HK
dc.identifier.scopusauthoridLeung, JCK=7202180349en_HK
dc.identifier.scopusauthoridLai, KN=7402135706en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats